Skip to content
CT-26 Mouse Model
Colorectal cancer remains one of the leading causes of cancer-related deaths around the world. The CT26 cell line is an N-nitroso-N-methylurethane (NNMU) induced, undifferentiated colon carcinoma cell line. It can be implanted subcutaneously or orthotopically to further tumor immunogenicity and development of novel therapeutics.
We have characterized the CT26 mouse model of colon carcinoma expressed as a flank model in BALB/c mice. With subcutaneous implantation on a mouse’s flank, tumor growth can easily be monitored allowing for quick testing of therapeutic agents and facilitation of downstream analysis such as flow cytometry and histology.
Fast Growing and Reproducible
A high take rate and fast-growing tumors present in our CT26 syngeneic model allow for efficient and reproducible analysis of therapeutics.
Metastatic Potential
CT26 cells have been shown to metastasize the liver, lungs and lymph nodes, making it a valuable model for studying cancer metastasis.
Immune Response and Treatments
The integrity of the immune system in a syngeneic model allows for the assessment of immune cell infiltration, cytokines response and development of immunotherapies or chemo-immune therapy combination.
CT-26 Murine Colorectal Carcinoma Model
CT26 is a well-studied rapid growing highly metastatic carcinoma for both flank and orthotopic models.
Commonly Requested Endpoints
Histopathology
Our customizable histopathological analysis can help evaluate tumor microenvironments, track tumor progression and metastases and inform treatment decisions.
Flow Cytometry
Our flow cytometry expertise can help characterize tumor-infiltration T lymphocytes, identity immune biomarkers, and so much more.